RESTATED AGREEMENT
BETWEEN HYMEDIX INTERNATIONAL, INC.
AND
PROCYTE CORPORATION
This RESTATED AGREEMENT (this "Agreement"), dated as of NOVEMBER 20TH
1997, is entered into by and between PROCYTE CORPORATION, a Washington
corporation ("ProCyte"), and HYMEDIX INTERNATIONAL, INC., a Delaware corporation
("Hymedix").
RECITALS
A. ProCyte and Hymedix entered into an agreement dated as of November
15, 1995 relating to certain polymer technology of Hymedix (the "Original
Agreement").
B. The parties now desire to amend and restate the Original Agreement
as set forth below, which among other things reduces the scope of ProCyte's
license rights, changes the consideration to be paid by ProCyte (i.e., to a one
time payment and delivery of material) and reduces certain obligations of the
parties to each other.
AGREEMENT
NOW, THEREFORE, in consideration of the promises and covenants
contained herein, the parties agree as follows:
SECTION 1. DEFINITIONS
As used herein:
1.1 "Affiliate" shall mean, with respect to a party, any other business
entity which directly or indirectly controls, is controlled by, or is under
common control with, the party. The direct or indirect ownership of at least
fifty percent (50%) of the voting securities of a business entity, or of an
interest in the assets, profits or earnings of a business entity, shall be
deemed to constitute control of the business entity. The current Affiliate of
Hymedix is its parent corporation Hymedix, Inc., a Delaware corporation. ProCyte
currently has no Affiliates.
1.2 "Europa Agreement" shall mean the Distribution, Know-how Transfer,
Licensing and Manufacturing and Supply Agreement dated August 21, 1995 between
Europa Magnetics Corporation Limited. incorporated under the laws of England
("Europa"), and Hymedix, as
-2-
supplemented and amended by a Supplemental Agreement dated November 15, 1995.
1.3 "Excluded Territory" shall mean the countries set forth in Exhibit
1.3 attached hereto so long as the Europa Agreement is in effect.
1.4 "FDA" shall mean the U.S. Food and Drug Administration or any
successor entity thereto.
1.5 "Field" shall mean wound care, including, but not limited to, the
treatment, management or care of any acute or chronic wound by dressings, by the
delivery of drugs or other agents to the wounds or by other methods or products,
whether such wound is caused, for example, by diabetic, venous stasis or
decubitus ulcers, by injury, by surgery, by bums or by other events or means.
1.6 "Important Patent Rights" shall mean those patents and patents
issuing on those patent applications identified in paragraphs 1, 3, 5, 10, 11
and 15 of Exhibit 1.8 (i.e., U.S. patents nos. 4,943,618, 5,252,692, 4,379,874,
4,420,589, 4,331,783 and U.S. patent application no. 08/201,357), and any
foreign counterparts, divisions, extensions, reexaminations, reissues,
substitutions. renewals, continuations or continuations in part thereof.
1.7 "Licensed Technology" shall mean the Patent Rights and all
copyrights, trade secrets and know-how owned or controlled (including licensed)
by Hymedix or an Affiliate of Hymedix as of the date of the Original Agreement
or thereafter (including after the date hereof) relating to polymers, hydrogels
or drug delivery, including, but not limited to, HYPAN structural hydrogels,
HYPAN transient network hydrogels, HYPAN, Ionic HYPAN SA. Taupan, Tpan, HyQ and
any improvements thereto. Trade secrets and know-how include, but are not
limited to, data, materials, scientific and technical information, formulations,
methods of manufacture, mechanisms of action. sources, clinical uses and
results, regulatory filings, testing protocols, packaging, suppliers of raw
materials and packaging, etc.
1.8 "Patent Rights" shall mean the patents and patent applications set
forth in Exhibit 1.8 attached hereto, any foreign counterparts thereof, any
other patents or patent applications owned or controlled (including licensed) by
Hymedix or its Affiliates as of the date of the Original Agreement or thereafter
(including after the date hereof) relating to polymers, hydrogels or drug
delivery in the Territory and any patents issuing thereon and any divisions,
extensions. reexaminations.
-3-
reissues. substitutions, renewals. continuations or continuations in part
thereof.
1.9 "Product" shall mean any product for the Field that incorporates,
is based on or is made through the use of, any of the Licensed Technology and
that uses absorbent polymers in the form of beads, pellets, strands or similar
form, which are encased in or incorporated into a permeable encasement.
1.10 "SKY" shall mean S.K.Y. Polymers, Inc., a Delaware corporation,
that is majority-owned and controlled by Xx. Xxxxxxxx Xxxx.
1.11 "Territory" shall mean the entire world, except the Excluded
Territory shall be excluded to the extent the Licensed Technology for the Field
is licensed to Europa under the Europa Agreement for the Field. The Territory
shall be increased to the extent countries comprising the Excluded Territory are
dropped from the territory covered by the Europa Agreement or to the extent
Europa's license rights under the Europa Agreement to the Intellectual Property
(as defined in the Europa Agreement), which is included in the Licensed
Technology, are reduced.
SECTION 2. GRANT OF RIGHTS
Subject to the terms of this Agreement, Hymedix hereby grants to
ProCyte the sole and exclusive license under the Licensed Technology to make,
have made, use and sell Products in the Territory for the Field. The foregoing
license shall be exclusive even as to Hymedix and its Affiliates and shall
include the right of ProCyte to sublicense others. ProCyte shall notify Hymedix
within ten (10) days after granting any sublicenses.
SECTION 3. PAYMENT
ProCyte shall pay Hymedix one hundred twenty-five thousand dollars
($125,000) within ten (10) days of the date of this Amendment as a payment in
full for all of the obligations, licenses, representations and warranties of
Hymedix, under the Agreement and shall not be obligated to make any further
payments to Hymedix under the Original Agreement or this Agreement, except for
royalties accruing under the Original Agreement through the date of this
Agreement. In addition, in the event the Europa Agreement is modified, amended,
terminated or adjusted to the satisfaction of ProCyte, such that the "Territory"
hereunder becomes worldwide, ProCyte shall pay Hymedix twenty-five thousand
dollars ($25,000) within ten (10) days after receiving written confirmation
-4-
thereof. It is recognized and agreed that Hymedix will retain its rights to the
two hundred thousand (200,000) shares of common stock of ProCyte in accordance
with the Stock Acquisition Agreement dated as of November 15, 1995 between the
parties, the last fifty thousand (50,000) shares of which will vest (and not
longer be subject to a risk of forfeiture) on November 15, 1997. Upon payment of
such one hundred fifty thousand dollars ($150,000), ProCyte's license under
Section 2 shall become fully paid up, irrevocable and non-terminable by Hymedix.
SECTION 4. SUPPLY OF MATERIAL
4.1 Pan from ProCyte
Within ten (10) days after the date of this Amendment, ProCyte will
ship to Hymedix with freight prepaid and without charge to Hymedix approximately
12,000 lbs. of polyacrylonitrile type A.
4.2 Pan from Hymedix
Hymedix shall have no further obligation to supply polyacrvlonitrile
type A under Section 6.1 of the Original Agreement.
SECTION 5. CONFIDENTIALITY
For a period of five (5) years after the date first written above, each
party shall keep confidential and not disclose or use (except as contemplated by
this Agreement) any proprietary or confidential information received from the
other party. The foregoing obligation of nondisclosure and nonuse shall not
apply to any information which (a) is independently developed by the other party
as shown by suitable documentary evidence, (b) is already known to the recipient
at the time of disclosure, (c) is or becomes public knowledge through no fault
of the recipient, (d) is received without an obligation of confidentiality from
a third party having the lawful right to disclose same, (e) the disclosing party
approves in writing may be disclosed, or (f) is required by law to be disclosed,
provided the recipient has used reasonable efforts to secure confidential
treatment of the information and given prior written notice to the other party.
With respect to Licensed Technology that is proprietary or confidential
information, ProCyte may disclose such information to its Affiliates,
sublicensees, consultants, outside contractors and clinical investigators, on a
need-to-know basis, on condition that such persons or entities agree to keep the
information confidential upon substantially the same terms as set forth herein,
(ii) ProCyte or its Affiliates or sublicensees may disclose the information to
Governmental or other
-5-
regulatory authorities to the extent that such disclosure is reasonably
necessary to obtain patents 6r authorizations to conduct clinical trials,
provided the disclosing party shall request confidential treatment thereof, and
(iii) ProCyte or its Affiliates or sublicensees may disclose the information to
the extent necessary to market Products commercially.
This Section 5 shall, after the date of the Original Agreement, apply
to all confidential or proprietary information that the parties disclosed to
each other or their Affiliates prior to the date thereof The parties'
obligations prior to the date of the Original Agreement are governed by a Mutual
Confidentiality and Non-disclosure Agreement dated May 30, 1995.
SECTION 6. JOINT PATENTS
The parties acknowledge and agree that there are no Joint Pan Patents
or Other Joint Patents (as such terms are defined in the Original Agreement).
SECTION 7. PATENT PROSECUTION AND MAINTENANCE
7.1 Patent Rights
Hymedix. shall, at its expense, diligently and in good faith file,
prosecute, issue and maintain the Important Patent Rights in the United States,
Germany, United Kingdom and Japan. Hymedix shall confer with ProCyte and its
counsel regarding the filing, prosecution, issuance and maintenance of such
Important Patent Rights and shall provide to ProCyte copies of any official
action within thirty (30) days of receipt and advance copies of, with the
opportunity for ProCyte to discuss and offer proposed changes to, any proposed
filing, submission or other correspondence by Hymedix or its licensors and
patent counsel. In the event Hymedix elects to abandon or not file on any
Important Patent Rights, it shall promptly notify ProCyte (but in any event no
later than thirty (30) days in advance of any deadline) and allow and assist
ProCyte, at ProCyte's election and expense, to pursue such Important Patent
Rights, in which event such Important Patent Rights shall be assigned to ProCyte
and nonexclusively licensed to Hymedix by ProCyte for all purposes not related
to Products.
-6-
7.2 Cooperation
Each party shall cooperate and assist the other party in connection
with the filing, prosecution, issuance, reexamination and maintenance of Patent
Rights. Where appropriate, each party shall sip, or cause to have signed, all
documents relating to the patent applications or patents for the Patent Rights.
SECTION 8. ENFORCEMENT OF PATENTS
8.1 Exclusive License Rights
Upon learning of the infringement of the Patent Rights in the Territory
by a Product made, used or sold by other than ProCyte or its Affiliates or
sublicensees, a party shall promptly notify the other party in writing of the
infringement and the evidence pertaining to such infringement. ProCyte shall
have three (3) months from the date of learning of the infringement to xxxxx the
infringement or to file suit against at least one of the infringers, at its sole
expense, following consultation with Hymedix. ProCyte shall not be obligated to
bring or maintain more than one such suit at any time with respect to infringers
of the same patent. If counsel reasonably concludes that Hymedix is a necessary
or indispensable party to such suit, ProCyte may use the name of, or join,
Hymedix.
If ProCyte does not bring the suit within the time set forth in the
preceding paragraph, Hymedix shall have the right to take whatever action it
deems appropriate in its own name or, if required by law, in the name of ProCyte
whose exclusive license rights are being infringed.
All monies recovered upon the final judgment or settlement of any
infringement suit shall, after reimbursement of the expenses of the parties
bringing any such suit (including reasonable attorneys' fees), be shared by the
parties in a ratio of 85:15 where eighty-five percent (85%) goes to the party
who brought the suit and fifteen percent (15%) goes to the other party.
8.2 Assistance
Both parties shall fully cooperate with and assist each other in
matters pertaining to infringement suits brought under Section 8. 1.
-7-
8.3 Settlement
The party bringing the infringement suit covered by this Section 8
shall not settle the suit or otherwise consent to an adverse judgment in such
suit in a manner that diminishes the rights or interests of the other party
without the other party's written consent, which consent shall not be
unreasonably withheld. The other party shall have the right to participate, at
its expense and with counsel of its choosing, in an infringement suit brought by
the other party to the extent its rights in any patents or other proprietary
rights are being challenged.
SECTION 9. WARRANTIES AND REPRESENTATIONS
9.1 Both Parties
Each party hereby represents and warrants to the other that:
(a) It (i) is a corporation duly organized, validly existing and in
good standing under the laws of the state in which it is incorporated, (ii) has
the corporate power and authority and the legal right to own and operate its
property and assets, to lease the property and assets it operates under lease,
and to carry on its business as it is now being conducted, and (iii) is in
compliance with all requirements of applicable law, except to the extent that
any noncompliance would not have a material adverse effect on its properties,
business, financial or other condition or ability to perform its obligations
under this Agreement.
(b) It (i) has the corporate power and authority and the legal right to
enter into this Agreement and to perform its obligations hereunder and (ii) has
taken all necessary corporate action on its part to authorize the execution and
delivery of this Agreement and the performance of its obligations hereunder.
This Agreement has been duly executed and delivered on its behalf and
constitutes a legal, valid and binding obligation, enforceable against it in
accordance with its terms.
(c) All necessary consents, approvals and authorizations of all
governmental authorities and other persons required to be obtained in connection
with its execution, delivery and performance of this Agreement have been
obtained.
(d) Notwithstanding anything to the contrary in this Agreement, its
execution, delivery and performance of this Agreement (i) will not conflict with
or violate any requirement of applicable laws or regulations
-8-
and (ii) will not conflict with, violate or breach or constitute a default or
require any consent under any of its contractual obligations.
9.2 Hymedix
Hymedix hereby represents and warrants to ProCyte that:
(a) Notwithstanding anything to the contrary in this Agreement, its
execution, delivery and performance of this Agreement will not conflict with,
violate, breach or constitute a default or require any consent under any
contractual obligations of its Affiliates, including Hymedix, Inc.
(b) Hymedix and its Affiliates have not granted, and will not grant
during the term of this Agreement. any rights or licenses in the Licensed
Technology in the Territory for Products.
(c) All patents and patent applications included in the Patent Rights
have been assigned to Hymedix or, with respect to items 16 through 26 on Exhibit
1.8, have been licensed (with right to sublicense) to Hymedix by SKY.
(d) Except for Licensed Technology licensed by Hymedix from SKY, all
the current Licensed Technology is owned by Hymedix and none of it is licensed
from third parties. The Licensed Technology is free and clear of any liens,
claims, encumbrances or rights of others for use in the Territory for the Field.
(e) True and correct copies of the Europa Agreement have been delivered
to ProCyte, which has not been modified. changed, waived or materially breached
in any respect.
(f) Hymedix or its Affiliates have not received or been notified of any
claim of infringement or misappropriation of any alleged rights asserted by
another party that relate to the Licensed Technology in the Territory for the
Field.
(g) The making, using and selling of polymers and hydrogels described
in the patents and patent applications and other Products based on the Licensed
Technology in the Field will not infringe any rights of others and will not
require a license from, or royalty payment to, another party, other than to SKY,
which Hymedix shall pay.
(h) Hymedix and its Affiliates are not aware of any patents. pending
patent applications or proprietary rights of any third party which
-9-
could materially affect the ability of ProCyte to use the Licensed Technology as
licensed hereunder.
(i) SKY or Xx. Xxxxxxxx Xxxx does not have any patents, pending patent
applications, patentable inventions or trade secrets that have not been licensed
to Hymedix and included in the Licensed Technology in the Territory that could
be useful for Products.
(j) All consultants and employees of Hymedix and its Affiliates are
obligated to keep confidential and not disclose to others any of the Licensed
Technology or information received from ProCyte upon terms, substantially the
same as those set forth in Section 5.
(k) Hymedix and its Affiliates are not aware of any party that has
infringed or misappropriated, or is or may soon be infringing, the Licensed
Technology in the Territory for the Field.
9.3 ProCyte
ProCyte hereby represents and warrants to Hymedix that all consultants
and employees of ProCyte are obligated to keep confidential and not disclose to
others any of the Licensed Technology or information received from Hymedix upon
terms substantially the same as those set forth in Section 5.
SECTION 10. COVENANTS
Hymedix covenants and agrees that:
10.1 Hymedix and its Affiliates shall not knowingly sell or provide,
whether directly or indirectly, any form of DuPont Pan or other form of
polyacrvlonitrile, polymers, HYPAN or product to anyone who Hymedix or its
Affiliates know or have reason to suspect will use or sell such material in the
Territory for Products.
10.2 Hymedix shall not increase the rights of Europa in the Excluded
Territory for Products without the prior written consent of ProCyte.
SECTION 11. INDEMNIFICATION
ProCyte shall indemnify and hold harmless Hymedix. its Affiliates,
directors, employees and agents from any liability for damage to or loss of
property or injury to or death of any persons arising out of ProCyte's
-10-
possession or use of the Licensed Technology, except to the extent such damage,
loss, injury or death results from the negligence or willful misconduct of
Hymedix. Upon receipt by Hymedix of any claim or suit with respect to which
ProCyte is required to provide indemnification hereunder, Hymedix shall promptly
notify ProCyte and permit ProCyte to handle and control the defense of such
claim or suit. ProCyte shall have the sole right to settle such claim or suit.
Hymedix shall indemnify and hold harmless ProCyte, its Affiliates,
directors, employees and agents from any liability, claim. damage, loss, cost or
expense (including reasonable attorneys' fees) arising from or related to any
breach of this Agreement by Hymedix. (including a breach of representation or
warranty).
SECTION 12. TRADEMARKS
ProCyte shall reassign to Hymedix all right, title and interest in and
to the registered trademark "HySorb" that had been assigned to ProCyte pursuant
to Section 17.1 of the Original Agreement. ProCyte's right and license to use
any trademarks of Hymedix is hereby terminated.
SECTION 13. TERM AND TERMINATION
13.1 Term
This Agreement shall remain in full force and effect until the
expiration of the last to expire of any patents included in the Patent Rights.
Upon expiration of the term of this Agreement, ProCyte shall have a fully
paid-up, royalty-free, perpetual license to use the Licensed Technology
nonexclusively in the Territory for Products.
13.2 Termination
(a) ProCyte shall have the right to terminate this Agreement at any
time upon sixty (60) days' prior written notice to Hymedix.
(b) If ProCyte fails to makes the payment due under Section 3 to
Hymedix, Hymedix shall have the right to terminate this Agreement fifteen (15)
days after giving ProCyte notice of such failure and Hymedix's intent to
terminate unless ProCyte makes such payment within such fifteen (15) day period.
-11-
13.3 Disposition of Products
Upon termination of this Agreement or a portion of the license, ProCyte
(and its Affiliates and sublicensees) shall have the right to complete any work
in progress and sell or otherwise dispose of any affected Product within the
next twelve (12) months.
SECTION 14. MISCELLANEOUS
14.1 Counterparts
This Agreement may be executed in two or more counterparts, each of
which shall be deemed an original, but all of which together shall constitute
one and the same instrument.
14.2 Modification
No amendment or modification hereof shall be valid or binding upon the
parties unless made in writing and signed by authorized representatives of the
parties.
14.3 Integration
This Agreement embodies the entire understanding of the parties and
shall supersede all previous communications, representations or understandings,
either oral or written, between the parties relating to the subject matter
hereof.
14.4 Severability
In case any one or more of the provisions contained in this Agreement
shall for any reason be held to be invalid, illegal or unenforceable in any
respect, such invalidity, illegality or unenforceability shall not affect any
other provisions hereof, but this Agreement shall be construed as if such
invalid or illegal or unenforceable provisions had never been contained herein.
14.5 Independent Contractors
Nothing in this Agreement shall constitute or be deemed to constitute a
partnership or agency between the parties hereto.
-12-
14.6 Headings
The headings of this Agreement are inserted for convenience only and
shall not be used in the interpretation of this Agreement.
14.7 Survival
The rights and obligations of the parties under Sections 5, 11, 13.1
(in the case of expiration), and 13.3 and any accrued obligations shall survive
expiration or termination of this Agreement.
14.8 Governing Laws
This Agreement shall be governed by and construed in accordance with
the laws of the State of Washington (regardless of its or any other
jurisdiction's choice-of-law principles).
14.9 Use of Names, Trade Names and Trademarks
Nothing contained in this Agreement shall be construed as conferring
any right to use in advertising, publicity or other promotional activities any
name, trade name, trademark or other designation of either party hereto
(including any contraction, abbreviation or simulation of any of the foregoing)
except where, upon advice of counsel, such use is required to comply with any
law or regulation of a governing body having jurisdiction over a party or over
the making, using or selling of any Product.
14.10 Notices and Communications
Any notice or any other communication required or permitted to be given
to a party pursuant hereto shall be sufficiently given if delivered personally
or by telecopy or express courier service (expenses prepaid) to the address set
forth below:
ProCyte: ProCyte Corporation
X.X. Xxx 000
Xxxxxxx, XX 00000
X.X.X.
Attn: President
FAX: (000) 000-0000
-13-
Hymedix: Hymedix International, Inc.
0000 Xxxxx 000
Xxxxxx, XX 00000
X.X.X.
Attn: President
FAX: (000) 000-0000
or to such other address as the party shall designate by written notice given to
the other party.
14.11 Waivers
No waivers of any right under this Agreement shall be deemed effective
unless contained in a writing signed by the party charged with such waiver, and
no waiver of any right arising from any breach or failure to perform shall be
deemed to be a waiver of any future right or of any other right arising under
this Agreement.
14.12 Review of Agreement
This Agreement has been submitted to the scrutiny of both parties and
their counsel and shall be given a fair and reasonable interpretation in
accordance with the words hereof, without consideration or weight being given to
its being drafted by or for one of the parties.
14.13 Rights of Bankruptcy
All rights in the Licensed Technology granted under or pursuant to this
Agreement by Hymedix are, and shall otherwise be deemed to be, for purposes of
Section 365(n) of the U.S. Bankruptcy Code, licenses of rights to "intellectual
property" as defined under Section 101 of the U.S. Bankruptcy Code. ProCyte, as
licensee of such rights under this Agreement, shall retain and may fully
exercise all its rights and elections under the U.S. Bankruptcy Code. In the
event of the commencement of a bankruptcy proceeding by or against Hymedix under
the U.S. Bankruptcy Code, ProCyte shall be entitled to complete access to (or a
complete duplicate of. as appropriate) any such intellectual property and all
embodiments of such intellectual property, and the same. if not already in
ProCyte's possession, shall be promptly delivered to ProCyte (a) upon any such
commencement of a bankruptcy proceeding upon ProCyte's written requests
therefor, unless Hymedix elects to continue to perform all of its obligations
under this Agreement or (b) if not delivered under (a) above, upon the rejection
of this Agreement by or on behalf of Hymedix and upon written request therefor
by ProCyte.
-14-
IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be
duly executed as of the date first above written.
PROCYTE CORPORATION
BY /s/ Xxxx X. Xxxxxxxx
______________________________________________
HYMEDIX INTERNATIONAL, INC.
BY /s/ Xxxxxxx Xxxxxxx
______________________________________________
-15-
EXHIBIT 1.3
Excluded Territory
Afghanistan
Bahrain
Bangladesh
Bhutan
Brunei
Burma
Republic of China, including Xxxxxx, Xxxxxxxx Xxxxx
Xxxxxx
Xxxx Xxxx
Xxxxx
Indonesia
Iran
Iraq
Israel
Japan
Xxxxxx
Xxxxxxxxx
Xxxxx (Xxxxx xxx Xxxxx)
Xxxxxx
Xxxx
Lebanon
Malaysia
Maldives
Xxxxxxxx Islands
Mongolia
Nepal
Oman
Pakistan
Philippines
Qatar
Saudi Arabia
Singapore
Sri Lanka
Syria
Turkey
Thailand
United Arab Emirates
Vietnam
Yemen (Aden and Sana)
-16-
EXHIBIT 1.8
Patents and Patent Applications
1. Patent No.: U.S. Patent No. 4,943,618
Title: METHOD FOR PREPARING POLYACRYLONITRILE
COPOLYMERS BY HETEROGENEOUS REACTION
OF POLYACRYLONITRILE AQUAGEL
Serial No.: 135,070
Filed: December 18, 1987
Issued: July 24, 1990
Assignee: Hymedix International, Inc.
Corresponding Foreign:
2. Appl. No.: European Application No. 88311824.2
Title: METHOD FOR PREPARING POLYACRYLONITRILE
COPOLYMERS BY HETEROGENEOUS REACTION
OF POLYACRYLONITRILE AQUAGEL
Status: Pending
3. Patent No.: U. S. Patent No. 5,252,692
Title: HYDROPHILIC ACRYLIC COPOLYMERS AND
METHOD OF PREPARATION
Serial No.: 617,177
Filed: November 23, 1990
Issued: October 12, 1993)
Assignee: Hymedix International. Inc.
4. Patent No.: U. S. Patent No. 5,218,039
Title: PAN EMULSION
Serial No.: 043,327
Filed: April 28.1987
Issued: June 8, 1993
Assignee: Hymedix International, Inc.
5. Patent No.: U.S. Patent No. 4,379,874
Title: POLYMER COMPOSITION COMPRISING
POLYACRYLONITRILE POLYMER AND
MULTI-BLOCK COPOLYMER
Serial No.: 166,032
Filed: July 7, 1980
Issued: April 12, 1983
Assignee: Hymedix International, Inc.
-17-
Corresponding Foreigns:
6. Patent No.: EP 094 980
Title: POLYMER COMPOSITION COMPRISING
POLYACRYLONITRILE POLYMER AND
MULTI-BLOCK COPOLYMER
7. Patent No.: JP 88028459
Title: POLYMER COMPOSITION COMPRISING
POLYACRYLONITRILE POLYMER AND MULTI-
BLOCK COPOLYMER
8. Patent No.: CA 1,177,190
Title: POLYMER COMPOSITION COMPRISING
POLYACRYLONITRILE POLYMER AND MULTI-
BLOCK COPOLYMER
9. Patent No.: DE 3278362
Title: POLYMER COMPOSITION COMPRISING
POLYACRYLONITRILE POLYMER AND MULTI-
BLOCK COPOLYMER
10. Patent No.: U.S. Patent No. 4,420,589
Title: POLYMER COMPOSITION INCLUDING
POLYACRYLONITRILE POLYMERS AND
PROCESS FOR PREPARING SAME
Serial No.: 423,731
Filed: September 27, 1982
Issued: December 13, 1983
Assignee: Hymedix International, Inc.
11. Patent No.: U. S. Patent No. 4,331,783
Title: NOVEL BLOCK COPOLYMERS INCLUDING
ACRYLONITRILE SEQUENCES AND GLUTARIMIDE
UNITS AND PROCESSES FOR PREPARING SAME
Serial No.: 188,224
Filed: September 17, 1980
Issued: May 25, 1982
Assignee: Hymedix International, Inc.
-18-
12. Patent No.: U.S. Patent No. 4,369,294
Title: NOVEL BLOCK COPOLYMERS INCLUDING
ACRYLONITRILE SEQUENCES AND
GLUTARDAIDE UNITS AND PROCESSES
FOR PREPARING SAME
Serial No.: 323,468
Filed: November 20, 1981
Issued: January 18, 1983
Assignee: Hymedix International, Inc.
13. Patent No.: U. S. Patent No. 4,337,327
Title: NOVEL BLOCK COPOLYMERS INCLUDING
ACRYLONITRILE SEQUENCES AND SEQUENCES
INCLUDING UNITS DERIVED FROM
GLUTARIMIDE UNITS AND PROCESSES FOR
PREPARING SAME
Serial No.: 188,060
Filed: September 17, 1980
Issued: June 29, 1982
Assignee: Hymedix International, Inc.
14. Patent No.: U.S. Patent No. 4,370,451
Title: NOVEL BLOCK COPOLYMERS, INCLUDING
ACRYLONITRILE SEQUENCES AND SEQUENCES
INCLUDING UNITS DERIVED FROM
GLUTARIMIDE UNITS AND PROCESSES
FOR PREPARING SAME
Serial No.: 346,417
Filed: February 8, 1982
Issued: January 25, 1983
Assignee: Hymedix International, Inc.
15. Appl. No.: U.S. Serial No. 08/201,357
Title: NOVEL NITROGEN-CONTAINING DRUG FORMS
FOR CONTROLLED RELEASE
Filed: February 24, 1994
Status: Pending
Assignee: Hymedix International, Inc.
-19-
16. Patent No.: U.S. Patent No. 4,021,382
Title: METHOD FOR THE PREPARATION OF
HYDROPHILIC SPONGY GELS
Serial No.: 434,944
Filed: January 21, 1974
Issued: May 3, 1977
Assignee: Ceskoslovenska akademie ved
17. Patent No.: U.S. Patent No. 4,053,442
Title: METHOD FOR MANUFACTURING SHAPED
ARTICLES FROM MULTI-BLOCK COPOLYMERS
Serial No.: 605,509
Filed: August 18, 1975
Issued: October 11, 1977
Assignee: Ceskoslovenska akademie ved
18. Patent No.: U.S. Patent No. 4,076,921
Title: METHOD FOR PRODUCING GLYCOL
METHACRYLATE OR GLYCOL ACRYLATE
POLYMERS AND COPOLYMERS
Serial No.: 297,390
Filed: October 13, 1972
Issued: February 28, 1978
Assignee: Ceskoslovenska akademie ved
19. Patent No.: U.S. Patent No. 4,107,121
Title: IONOGENIC HYDROPFULIC WATER-INSOLUBLE
GELS FROM PARTIALLY HYDROLYZED
ACRYLONITRILE POLYMERS AND COPOLYMERS,
AND A METHOD OF MANUFACTURING SAME
Serial No.: 633,786
Filed: November 20, 1975
Issued: August 15, 1978
Assignee: Ceskoslovenska akademie ved
20. Patent No.: U.S. Patent No. 4,110,529
Title: METHOD OF MANUFACTURING SPHERICAL
POLYMER PARTICLES FROM POLYMER
SOLUTIONS
Serial No.: 633,787
Filed: November 20,1975
Issued: August 29, 1978
Assignee: Ceskoslovenska akademie ved
-20-
21. Patent No.: U.S. Patent No. 4,123,406
Title: METHOD OF PREPARING SHAPED ARTICLES
FROM CROSS-LINKED HYDROGELS
Serial No.: 655,208
Filed: February 4, 1976
Issued: October 31, 1978
Assignee: Ceskoslovenska akademie ved
22. Patent No.: U.S. Patent No. 4,172,823
Title: METHOD OF PREPARING CROSS-LINKED
HYDROGELS
Serial No.: 927,345
Filed: July 24, 1978
Issued: October 30, 1979
Assignee: Ceskoslovenska akademie ved
23. Patent No.: U.S. Patent No. 4,173,606
Title: METHOD OF MANUFACTURING SHAPED
ARTICLES FROM CRYSTALLINE ACRYLONITRILE
POLYMERS AND COPOLYMERS
Serial No.: 895,366
Filed: April 11, 1978
Issued: November 6, 1979
Assignee: Ceskoslovenska akademie ved
24. Patent No.: U.S. Patent No. 4,183,884
Title: METHOD FOR MANUFACTURING HYDROGEL
TUBES
Serial No.: 737,051
Filed: November 1, 1976
Issued: January 15, 1980
Assignee: Ceskoslovenska akademie ved
25. Patent No.: U.S. Patent No. 4,228,056
Title: SHAPED ARTICLES FROM INSOLUBLE
HYDROGELS AND METHOD OF MANUFACTURING
SAME
Serial No.: 910,449
Filed: May 30, 1978
Issued: October 14, 1980
Assignee: Ceskoslovenska akademie ved
26. Patent No.: U.S. Patent No. 4,634,604
Title: METHOD FOR PRODUCING A BIOCONVATIBLE
LAYER ON THE SURFACE OF PARTICLES OF
POROUS SYNTHETIC SORBENTS
Serial No.: 622,671
Filed: June 20, 1984
Issued: January 6, 1987
Assignee: Ceskoslovenska akademie ved
